VERELAN PM Drug Patent Profile
✉ Email this page to a colleague
When do Verelan Pm patents expire, and what generic alternatives are available?
Verelan Pm is a drug marketed by Societal Cdmo and is included in one NDA.
The generic ingredient in VERELAN PM is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Verelan Pm
A generic version of VERELAN PM was approved as verapamil hydrochloride by EXELA PHARMA on March 30th, 1984.
Summary for VERELAN PM
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 78 |
| Clinical Trials: | 12 |
| Patent Applications: | 4,330 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VERELAN PM |
| What excipients (inactive ingredients) are in VERELAN PM? | VERELAN PM excipients list |
| DailyMed Link: | VERELAN PM at DailyMed |
Paragraph IV (Patent) Challenges for VERELAN PM
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| VERELAN PM | Extended-release Capsules | verapamil hydrochloride | 100 mg and 200 mg | 020943 | 1 | 2006-07-20 |
| VERELAN PM | Extended-release Capsules | verapamil hydrochloride | 300 mg | 020943 | 1 | 2006-05-19 |
US Patents and Regulatory Information for VERELAN PM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Societal Cdmo | VERELAN PM | verapamil hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020943-001 | Nov 25, 1998 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Societal Cdmo | VERELAN PM | verapamil hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020943-002 | Nov 25, 1998 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Societal Cdmo | VERELAN PM | verapamil hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020943-003 | Nov 25, 1998 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VERELAN PM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Societal Cdmo | VERELAN PM | verapamil hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020943-003 | Nov 25, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
| Societal Cdmo | VERELAN PM | verapamil hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020943-001 | Nov 25, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
| Societal Cdmo | VERELAN PM | verapamil hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020943-002 | Nov 25, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VERELAN PM
See the table below for patents covering VERELAN PM around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2637981 | ⤷ Try a Trial | |
| European Patent Office | 0250267 | CONTROLLED ABSORPTION PHARMACEUTICAL COMPOSITION | ⤷ Try a Trial |
| Japan | S635021 | ABSORPTION CONTROLLED DRUG COMPOSITION | ⤷ Try a Trial |
| Austria | 72975 | ⤷ Try a Trial | |
| Australia | 7452887 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
